Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

← catalyst calendar

NCT04490915 · results posted

Sponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
182actual
Sites
70
Countries
Austria, Belgium, Bulgaria +15

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2020-12-16actualWhen the study began enrolling
Primary completion2023-07-19actualThe date the last participant is measured for the primary outcome — the readout window
Study completionAug 2027estimatedThe whole study's end, after follow-up
First posted2020-07-29actualWhen this record first appeared on the registry
Results posted2025-02-05actualWhen the sponsor posted results to the registry
Record updated2026-05-11actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Congenital Adrenal Hyperplasia

Interventions

  • Drug: Crinecerfont — also filed as NBI-74788, Crenessity
  • Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF
Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24
measured Baseline, Week 24

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2021-11-30 · 7.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-08-10 · 1.1 MB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed